iStar Medical SA raises €40.1m
Glucoma transplant specialist iStar Medical SA has closed a Series C finanincing round led by LSP and Gimv.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2155 entries already.
Entries by Thomas Gabrielczyk
DPP3 triggers myocardial depression
Results presented at European Society of Cardiology Congress 2019 demonstrate a new disease mechanism predicting acute organ dysfunction in heart failure patients.
Pro-apoptotic protein blocks autoimmunity
A US-EU research team has found that a class of compounds that promote tumour cell death can also limit autoimmunity.
Immatics and Celgene enter $1.5bn deal
Celgene will pay $75m upfront to get an option on three cancer programmes developed by Immatics Biotechnologies.
Microbial feed company Unibio raises US$15m
Danish microbiology specialist Unibio International plc had completed a US$15m financing round led by West Hill Capital.
ADC Therapeutics and Freenome enter biomarker collaboration
US company Freenome will use its multiomics platform to develop response biomarkers to ADC Therapeutics’ Phase II antibody drug conjugate (ADC) ADCT-402.
GSK reaches endpoint in pivotal blood cancer study
GlaxoSmithKline plc announced belantamab mafodotin (GSK2857916) met the primary endpoint of overall response rate (ORR) in a pivotal Phase II trial in treatment-refractive multiple myeloma.
Swiss researchers report on metastasis switch
Researchers from Paul Scherrer Institute in Villingen, Switzerland, and Hoffmann La-Roche AG report in Cell they have solved the structure of a target relevant in metastasis.
Preclinical antibody stops rheumatoid arthritis
An antibody therapy that targets red blood cells (RBCs) unexpectedly showed anti-inflammatory effects and rapidly reversed rheumatoid arthritis and prevented lung injury in mouse models.
Nabriva receives FDA approval for novel antibiotics
Nabriva Therapeutics plc has got the go from the FDA to market its pleuromutilin antibiotic Xenleta (lefamulin), a protein synthesis blocker with new mode-of-action to treat community-acquired bacterial pneumonia.